<div id="readability-page-1"><p>DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $20.00, but opened at $20.85. DBV Technologies shares last traded at $19.5350, with a volume of 161,540 shares changing hands.</p><div><p><span></span><span>Get <strong>DBV Technologies</strong> alerts:</span></p></div><h2>Analysts Set New Price Targets</h2><ul><li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li></ul><p>Several equities analysts recently issued reports on DBVT shares. HC Wainwright  restated a &#34;buy&#34; rating and set a $20.00 price objective (up from $16.00) on shares of DBV Technologies in a research note on Wednesday, October 29th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of DBV Technologies in a report on Monday. Zacks Research raised shares of DBV Technologies from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Monday, September 29th. Wall Street Zen raised shares of DBV Technologies from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Friday, November 28th. Finally, Guggenheim started coverage on DBV Technologies in a report on Wednesday, December 3rd. They issued a &#34;buy&#34; rating and a $35.00 price target on the stock. One investment analyst  has rated the stock with a Strong Buy rating, four have given a Buy rating, one  has given a Hold rating and two have issued  a Sell rating to the stock. Based on data from MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $20.81.</p><p><b>Get Our Latest Stock Analysis on DBVT</b></p><h2>DBV Technologies Stock Down 3.2%</h2><p>The firm has a market cap of $753.10 million, a price-to-earnings ratio of -3.75 and a beta of -1.10. The stock's 50 day moving average is $14.55 and its 200 day moving average is $11.29. </p><h2>Institutional Trading of DBV Technologies</h2><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. Vivo Capital LLC bought a new stake in  DBV Technologies during the second quarter worth approximately $9,659,000.  Adage Capital Partners GP L.L.C. bought a new stake in shares of  DBV Technologies during the 2nd quarter worth $9,659,000.  MPM Bioimpact LLC purchased a new position in  DBV Technologies in the 2nd quarter worth about $9,649,000.  Octagon Capital Advisors LP purchased a new position in  DBV Technologies in the 2nd quarter worth about $9,315,000.  Finally, Millennium Management LLC lifted its stake in  DBV Technologies by 26.1% during the third quarter. Millennium Management LLC now owns 337,863 shares of the company's stock valued at $3,379,000 after buying an additional 69,849 shares in the last quarter. 71.74% of the stock is currently owned by institutional investors. </p><h2>DBV Technologies Company Profile</h2> (Get Free Report)<p>DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than DBV Technologies</li><li>3 Defense Stocks Set to Benefit From Increased Military Spending</li><li>Top 3 Winter Stocks With Solid Growth Opportunities</li><li>3 Stocks to Consider Buying in October</li><li>2026 Comeback Picks: 3 S&amp;P Laggards Poised to Break Out</li><li>What is a Dividend King? </li><li>Tesla Bulls See $500 Ahead—But Bears Warn of a Painful Reversal</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in DBV Technologies Right Now?</h2><p>Before you consider DBV Technologies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.</p><p>While DBV Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DBVT

<p>DBV Technologies (NASDAQ:DBVT) shares gapped up before trading on Thursday, opening at $20.85 from a previous close of $20.00. The stock last traded at $19.5350. Analysts have mixed ratings: HC Wainwright upgraded to 'buy' with a $20.00 target, Weiss Ratings rated 'sell (d-)', Zacks Research upgraded to 'hold', Wall Street Zen upgraded to 'hold', and Guggenheim initiated coverage with a 'buy' and $35.00 target. Institutional investors have recently increased their positions in DBV Technologies.</p>

DBV Technologies (NASDAQ:DBVT) Shares Gap Up - Should You Buy?